Cargando…

Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients

Lung cancer is the leading cause of cancer deaths worldwide and one of the most common types of cancers. The limited success of chemotherapy and radiotherapy regimes have highlighted the need to develop new therapies like antitumor immunotherapy. CD8+ T-cells represent a major arm of the cell-mediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Prado-Garcia, Heriberto, Romero-Garcia, Susana, Aguilar-Cazares, Dolores, Meneses-Flores, Manuel, Lopez-Gonzalez, Jose Sullivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483679/
https://www.ncbi.nlm.nih.gov/pubmed/23118782
http://dx.doi.org/10.1155/2012/741741
_version_ 1782248040402255872
author Prado-Garcia, Heriberto
Romero-Garcia, Susana
Aguilar-Cazares, Dolores
Meneses-Flores, Manuel
Lopez-Gonzalez, Jose Sullivan
author_facet Prado-Garcia, Heriberto
Romero-Garcia, Susana
Aguilar-Cazares, Dolores
Meneses-Flores, Manuel
Lopez-Gonzalez, Jose Sullivan
author_sort Prado-Garcia, Heriberto
collection PubMed
description Lung cancer is the leading cause of cancer deaths worldwide and one of the most common types of cancers. The limited success of chemotherapy and radiotherapy regimes have highlighted the need to develop new therapies like antitumor immunotherapy. CD8+ T-cells represent a major arm of the cell-mediated anti-tumor response and a promising target for developing T-cell-based immunotherapies against lung cancer. Lung tumors, however, have been considered to possess poor immunogenicity; even so, lung tumor-specific CD8+ T-cell clones can be established that possess cytotoxicity against autologous tumor cells. This paper will focus on the alterations induced in CD8+ T-cells by lung cancer. Although memory CD8+ T-cells infiltrate lung tumors, in both tumor-infiltrating lymphocytes (TILs) and malignant pleural effusions, these cells are dysfunctional and the effector subset is reduced. We propose that chronic presence of lung tumors induces dysfunctions in CD8+ T-cells and sensitizes them to activation-induced cell death, which may be associated with the poor clinical responses observed in immunotherapeutic trials. Getting a deeper knowledge of the evasion mechanisms lung cancer induce in CD8+ T-cells should lead to further understanding of lung cancer biology, overcome tumor evasion mechanisms, and design improved immunotherapeutic treatments for lung cancer.
format Online
Article
Text
id pubmed-3483679
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34836792012-11-01 Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients Prado-Garcia, Heriberto Romero-Garcia, Susana Aguilar-Cazares, Dolores Meneses-Flores, Manuel Lopez-Gonzalez, Jose Sullivan Clin Dev Immunol Review Article Lung cancer is the leading cause of cancer deaths worldwide and one of the most common types of cancers. The limited success of chemotherapy and radiotherapy regimes have highlighted the need to develop new therapies like antitumor immunotherapy. CD8+ T-cells represent a major arm of the cell-mediated anti-tumor response and a promising target for developing T-cell-based immunotherapies against lung cancer. Lung tumors, however, have been considered to possess poor immunogenicity; even so, lung tumor-specific CD8+ T-cell clones can be established that possess cytotoxicity against autologous tumor cells. This paper will focus on the alterations induced in CD8+ T-cells by lung cancer. Although memory CD8+ T-cells infiltrate lung tumors, in both tumor-infiltrating lymphocytes (TILs) and malignant pleural effusions, these cells are dysfunctional and the effector subset is reduced. We propose that chronic presence of lung tumors induces dysfunctions in CD8+ T-cells and sensitizes them to activation-induced cell death, which may be associated with the poor clinical responses observed in immunotherapeutic trials. Getting a deeper knowledge of the evasion mechanisms lung cancer induce in CD8+ T-cells should lead to further understanding of lung cancer biology, overcome tumor evasion mechanisms, and design improved immunotherapeutic treatments for lung cancer. Hindawi Publishing Corporation 2012 2012-10-17 /pmc/articles/PMC3483679/ /pubmed/23118782 http://dx.doi.org/10.1155/2012/741741 Text en Copyright © 2012 Heriberto Prado-Garcia et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Prado-Garcia, Heriberto
Romero-Garcia, Susana
Aguilar-Cazares, Dolores
Meneses-Flores, Manuel
Lopez-Gonzalez, Jose Sullivan
Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
title Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
title_full Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
title_fullStr Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
title_full_unstemmed Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
title_short Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
title_sort tumor-induced cd8+ t-cell dysfunction in lung cancer patients
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483679/
https://www.ncbi.nlm.nih.gov/pubmed/23118782
http://dx.doi.org/10.1155/2012/741741
work_keys_str_mv AT pradogarciaheriberto tumorinducedcd8tcelldysfunctioninlungcancerpatients
AT romerogarciasusana tumorinducedcd8tcelldysfunctioninlungcancerpatients
AT aguilarcazaresdolores tumorinducedcd8tcelldysfunctioninlungcancerpatients
AT menesesfloresmanuel tumorinducedcd8tcelldysfunctioninlungcancerpatients
AT lopezgonzalezjosesullivan tumorinducedcd8tcelldysfunctioninlungcancerpatients